Evaluation of Cu, Zn and Se levels in the North American Autism Spectrum Disorder Population


About this study

The purpose of this study is to confirm a correlation between metal ion dyshomeostasis (low Zn levels, abnormal Zn/Cu ratio, or low Selenium levels) in a North American population and the diagnosis of ASD using gold standard diagnostic instruments.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 24-47 months-old.
  • Males and females.                             
  • Diagnosis of Autism Spectrum Disorder with or without language impairment and  intellectual disability as determined by a clinical Dana Program Evaluation.

Exclusion Criteria:

  • Zinc supplements taken in the last 4 months.        

Inclusion Criteria - Healthy Controls:

  • 24-47 months-old.
  • Males and females.

Exclusion Criteria - Healthy Controls:


  • Patients who have a history of significant pre-maturity or are seen in the NICU follow up clinic.
  • Patients with concerns of developmental delay.
  • Patients with MCHAT score of 4 or higher or ASQ score below 35 in any Domain when those tests were completed.
  • Patients with seizures.
  • Zinc supplements taken in the last 4 months








Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sunil Mehta, M.D., Ph.D.

Closed for enrollment

Contact information:

Lindsay Stromback



More information


Publications are currently not available

Mayo Clinic Footer